CI

At a glance

ClinicalIndex Comparison Record
N/ACompleted· 81 enrolled
Drug / intervention
Substrate+mCPVA +1 moredevice
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT02571218
NCT02571218N/ACompleted
CompareCT.gov

Substrate-Targeted Catheter Ablation to Treat Persistent Atrial Fibrillation

Abbott Medical Devices·interventional·Posted Oct 8, 2015·Updated Jul 5, 2019

In Brief

A clinical study evaluating Substrate+mCPVA and mCPVA for Persistent Atrial Fibrillation. Completed, enrolled 81 participants across 1 site.

Detailed Summary

In this study, the investigators aim to identify and characterize, by means of an EnSite Velocity Research Software, the electrophysiological characteristics of substrates that sustain AF in patients with persistent AF and to test whether ablation of such patient-specific substrates might improve the acute and long-term success of conventional catheter ablation therapy.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsPersistent Atrial Fibrillation
CountriesItaly
Collaborators--

Timeline

N/ACompletedFinished
20162017201820192020202120222023202420252026
First PostedOct 8, 2015
Enrollment StartJul 1, 2015
Primary CompletionFeb 1, 2017
TodayJul 2, 2026
Enrollment to primary: 1.6 yearsPosted 10.7 years ago

Interventions

Substrate+mCPVAdevice

The intervention in the experimental arm includes using a research software (investigational device) to map AF substrate and guide ablation.

mCPVAdevice

The intervention in the active comparator arm includes using the commercially available EnSite Velocity mapping and ablation system for modified circumferential pulmonary vein ablation.